Kolon Life Science Inc. (KOSDAQ: 102940)

Kolon Life Science Statistics

Total Valuation

Kolon Life Science has a market cap or net worth of KRW 247.85 billion. The enterprise value is 347.38 billion.

Market Cap	247.85B
Enterprise Value	347.38B

Important Dates

The next estimated earnings date is Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Kolon Life Science has 12.42 million shares outstanding. The number of shares has increased by 0.46% in one year.

Shares Outstanding	12.42M
Shares Change (YoY)	+0.46%
Shares Change (QoQ)	+0.97%
Owned by Insiders (%)	18.06%
Owned by Institutions (%)	0.18%
Float	6.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.63
PB Ratio	1.93
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.12
EV / Sales	2.48
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.77

Financial Position

The company has a current ratio of 0.62, with a Debt / Equity ratio of 0.98.

Current Ratio	0.62
Quick Ratio	0.33
Debt / Equity	0.98
Debt / EBITDA	n/a
Debt / FCF	-3.16
Interest Coverage	-3.38

Financial Efficiency

Return on equity (ROE) is -58.21% and return on invested capital (ROIC) is -5.73%.

Return on Equity (ROE)	-58.21%
Return on Assets (ROA)	-4.33%
Return on Capital (ROIC)	-5.73%
Revenue Per Employee	333.19M
Profits Per Employee	-200.21M
Employee Count	421
Asset Turnover	0.41
Inventory Turnover	2.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-22.07%
50-Day Moving Average	20,692.40
200-Day Moving Average	22,750.10
Relative Strength Index (RSI)	55.61
Average Volume (20 Days)	17,986

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kolon Life Science had revenue of KRW 140.27 billion and -84.29 billion in losses. Loss per share was -7,367.96.

Revenue	140.27B
Gross Profit	13.24B
Operating Income	-23.80B
Pretax Income	-84.26B
Net Income	-84.29B
EBITDA	-15.35B
EBIT	-23.80B
Loss Per Share	-7,367.96

Balance Sheet

The company has 25.56 billion in cash and 125.10 billion in debt, giving a net cash position of -99.53 billion or -8,011.65 per share.

Cash & Cash Equivalents	25.56B
Total Debt	125.10B
Net Cash	-99.53B
Net Cash Per Share	-8,011.65
Equity (Book Value)	127.77B
Book Value Per Share	10,361.31
Working Capital	-68.85B

Cash Flow

In the last 12 months, operating cash flow was -29.78 billion and capital expenditures -9.83 billion, giving a free cash flow of -39.60 billion.

Operating Cash Flow	-29.78B
Capital Expenditures	-9.83B
Free Cash Flow	-39.60B
FCF Per Share	-3,187.89

Margins

Gross margin is 9.44%, with operating and profit margins of -16.97% and -60.09%.

Gross Margin	9.44%
Operating Margin	-16.97%
Pretax Margin	-60.07%
Profit Margin	-60.09%
EBITDA Margin	-10.95%
EBIT Margin	-16.97%
FCF Margin	-28.23%

Dividends & Yields

Kolon Life Science does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.46%
Shareholder Yield	-0.46%
Earnings Yield	-36.93%
FCF Yield	-15.98%

Stock Splits

The last stock split was on December 27, 2017. It was a forward split with a ratio of 1.5.

Last Split Date	Dec 27, 2017
Split Type	Forward
Split Ratio	1.5

Scores

Kolon Life Science has an Altman Z-Score of -0.07. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.07
Piotroski F-Score	n/a